cp-i

CPI-0610 carboxylic acid is an effective and selective small molecule inhibitor of bromine domain and outer end (BET) protein as a ligand of PROTAC target protein. CPI-0610 carboxylic acid may have anticancer and anticancer activities.

A2A receptor antagonist 1 (CPI-444 analog) is an inhibitor of the adenosine A2A receptor and A1 receptor with Ki values of 4 nM and 264 nM, respectively.

CPI-360 is a small molecule EZH2 inhibitor (IC50: 0.002 μM, EC50: 0.080 μM) that shows antitumor activity in an EZH200-dependent tumor xenograft model.

CPI1189 (REN-1189) is a TNF-a release inhibitor potentially for the treatment of sciatica and postherpetic neuralgia.

CPI-268456 is a compound which has bioactive.

Pomalidomide-NH-PEG6-amide-C2-CPI-1612 (compound 22 (dCE-1)) is a CBP/EP300 degrader. It consists of the CRBN ligand Pomalidomide, a 24-atom chain with 6 PEG units, and the HAT inhibitor CPI-1612. This compound exhibits antiproliferative effects on multiple myeloma cells LP1 (DC50 = 1.2 μM), MM1S, and various cancer cells, notably leukemia cells.

CPI-455 is a specific KDM5 inhibitor with IC50 value of 10 ± 1 nM for full-length KDM5A in enzymatic assays, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with target

CPI203 (CPI 203) is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4).

CPI098 is a potent and selective inhibitors for the bromodomains of CREBBP/EP300. CREBBP/EP300 bromodomains play a critical role in regulatory T cell biology. T cell recruitment to tumors is a major mechanism of immune evasion by cancer cells.

CPI-4203 is a selective inhibitor of KDM5 demethylases.

CPI703 is a novel potent and specific CBP/EP300 bromodomain inhibitor.

CPI-905 is a potent and selective EZH2 inhibitor with IC50 value of 39.5 nM.

CPI-455 is a specific KDM5 inhibitor.

CPI-455 analogue (CPI-455 analogue) is an analogue of CPI-455 which is a KDM5 inhibitor.

CPI-1328, an EZH2 inhibitor, has a K i value of 63 fM.

Tulmimetostat (CPI-0209) is an orally active EZH1/EZH2 inhibitor with antitumor activity, utilized in the study of ovarian cancer and advanced solid tumors.

CPI-203 is an effective BET bromodomain inhibitor (IC50: 37 nM for BRD4).

Devimistat (6,8-Bis(benzylthio)octanoic acid) , a lipoate analog, inhibits mitochondrial enzymes pyruvate dehydrogenase (PDH) and α-ketoglutarate dehydrogenase, disrupts tumor cell mitochondrial metabolism. It has potential chemopreventive and antineoplastic activities, and has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Advanced Cancer, and Pancreatic Cancer, among others.

CPI-1612 is a potent, orally active EP300/CBP histone acetyltransferase (HAT) inhibitor that acts on EP300 HAT (IC50: 8.1 nM). CPI-1612 exhibits anticancer effects.

CPI-169 racemate (CPI 169) is a potent, and selective EZH2 inhibitor with IC50 of 0.24 nM, 0.51 nM, and 6.1 nM for EZH2 WT, EZH2 Y641N, and EZH1, respectively.

CPI-637 is a selective and cell-active benzodiazepinone CBP/EP300 bromodomain inhibitor.

CPI-444 (V81444) is an antagonist of the adenosine A2A receptor.It reduces tumor area in mouse model of murine Her2/neu-expressing breast cancer.

Mupadolimab (CPI-006) is a humanized FC-γR binding deficient IgG1 anti-CD73 antibody with potential anticancer activity and activation of CD73POS B cells.

CPI-1205 is a highly potent and selective inhibitor of EZH2(IC50 : 0.002 μM, EC50 : 0.032 μM) .